You are here

Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies,
a novel class of therapeutic proteins based on single-domain antibody
fragments, for a range of serious and life-threatening human diseases,
including inflammation, haematology, oncology and pulmonary disease.